PFIZER REPORTS FIRSTQUARTER 2017 RESULTS
FirstQuarter 2017 Revenues of $12.8 Billion Reflecting 1 Operational Decline Unfavorably Impacted by One Less U.S. Selling Day and Two Fewer International Selling Days Compared to the PriorYear Quarter...
View ArticleNICE backs Janssens desperately needed Crohns disease drug
The National Institute for Health and Care Excellence NICE the costeffectiveness watchdog for England
View ArticleThe microbiome therapeutics market is estimated to reach USD 433.5 million by...
LONDON May 2 2017 PRNewswire The microbiome therapeutics market is expected to reach USD 433.5 million by 2025 based on a new study by Grand View Research Inc. Increasing funding initiatives and...
View ArticleSoligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial...
PRINCETON N.J. May 3 2017 PRNewswire Soligenix Inc. Nasdaq SNGX Soligenix or the Company a latestage biopharmaceutical company focused on developing and commercializing products to treat rare diseases...
View ArticleNICE recommends Janssen's firstofitskind Crohn's drug Stelara
Janssen has announced that it has secured recommendation from NICE for Stelara ustekinumab in the indication of moderately to severely active Crohns disease in adults who have proved unresponsive to...
View ArticleIrritable Bowel Disease IBD Patients Experience Invisible and Lifealtering...
PHILADELPHIA PAMarketwired May 03 2017 IBD In America 2017 a national survey by Health Union of more than 4000 individuals diagnosed with Crohn's disease or ulcerative colitis UC reveals many people...
View ArticleVagus nerve stimulation promising in Crohn's disease
HealthDayVagus nerve stimulation may represent a new therapeutic option for patients with Crohn's disease CD according to a report published online April 18 in the Journal of Internal Medicine.
View ArticleFive U.S. Delegates Among 100 Young Leaders Appointed to Help Tackle Global...
RESEARCH TRIANGLE PARK N.C. May 3 2017 PRNewswire Crop Science a division of Bayer is pleased to announce that five millennials in agriculture have been selected to represent the U.S. at the third...
View ArticleCORRECTION Health Union
PHILADELPHIA PAMarketwired May 04 2017 In the news release "Irritable Bowel Disease IBD Patients Experience Invisible and Lifealtering Burdens" issued Wednesday May 03 2017 by Health Union we are...
View ArticleImmune Pharmaceuticals Announces Private Placement of up to $3.4 Million
NEW YORK May 4 2017 PRNewswire Immune Pharmaceuticals Inc. Nasdaq IMNP "Immune" or the "Company" today announced that it has entered into definitive agreements with several institutional investors for...
View ArticleAbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New...
NORTH CHICAGO Ill. May 4 2017 PRNewswire AbbVie NYSE ABBV a global biopharmaceutical company today announced that data from 20 abstracts in gastroenterology and hepatology programs will be presented at...
View ArticleExploration in the Interactions Between the Mycobiome and Bacteriome Webinar
In this webinar which LabRoots will host May 22 attendees will discover the impact of mycobiome and bacteriome has on health and the development of Crohns disease.Yorba Linda Ca PRWEB May 04 2017...
View ArticleKey Patent Issues Covering Protagonist Therapeutics' Oral Peptide IL23...
MILPITAS Calif. May 4 2017 PRNewswire Protagonist Therapeutics Inc. NASDAQ PTGX today announced that a key patent has issued covering orally stable peptide inhibitors of the interleukin23 receptor...
View ArticleJanssen's Crohn's disease drug gains NICE backing
The National Institute for Health and Care Excellence has recommended use of Stelara or ustekinumab from Janssen as a treat More
View ArticleInDex Pharmaceuticals Will Participate in the Digestive Disease Week DDW
STOCKHOLM May 05 2017 PRNewswire InDex Pharmaceuticals Holding AB publ today announced that the company will present two posters at the Digestive Disease Week DDW. DDW is the largest congress in the...
View ArticleGalapagos NV GLPG Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryGalapagos NV Galapagos is a clinical stage biotechnology company that discovers and develops pharmaceutical products. The company's product pipeline encompasses investigational candidates...
View ArticleGalapagos presents three posters on filgotinib in Crohn's disease at DDWÂ 2017
Mechelen Belgium; 7 May 2017 16.35 CET Galapagos NV Euronext & NASDAQ GLPG announces the presentation of three posters from the Phase 2 FITZROY study of the investigational agent filgotinib in...
View ArticleTakeda Release New RealWorld Analyses Support Effectiveness And Safety Of...
Life Sciences Jobs ...
View ArticleArena Pharmaceuticals Inc ARNA Financial and Strategic SWOT Analysis Review...
Arena Pharmaceuticals Inc ARNA Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by...
View ArticleNew RealWorld Analyses Support Effectiveness and Safety of EntyvioÂ...
OSAKA Japan May 8 2017 PRNewswire Takeda Pharmaceutical Company Limited TSE 4502 "Takeda" today announced the presentation of eight realworld analyses supporting the effectiveness and safety of...
View Article